Hims & Hers Health (NYSE: HIMS) reported another blowout quarter recently, but the stock didn't get the type of pop that ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

Hims & Hers is a rapidly emerging player in telehealth and wellness, catering to millennials and Gen Z. The company reported ...

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

TD Cowen analyst Jonna Kim raised the firm’s price target on Hims & Hers to $28 from $25 and keeps a Buy rating on the shares. The firm said HIMS has ample opportunities to grow weight loss as a ...

Hims' third-quarter results topped expectations, driven in part by revenue from its weight-loss drugs. The company said it ...

Bearish flow noted in Hims and Hers Health with 30,788 puts trading, or 9x expected. Most active are Dec-24 21 puts and Dec-24 22 puts, with ...

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions ...

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...

With a 77% revenue increase and a growing subscriber base, Hims & Hers Health Inc (HIMS) continues to innovate in ...